Search results for: 'partnering agreements what alnylam pharmaceutical 2016 2016'

Analyze co-development deals in pharma and biotech from 2016 to 2026. Includes financials, deal terms, and access to actual contracts where available.

Comprehensive Business Intelligence for Strategic Decision-Making

Track JV activity across pharma and biotech with real-world examples, financial terms, and partnering trends—includes access to contract documents where available.

The Leading Partnering Intelligence Platform for Pharma, Biotech and Diagnostic Dealmakers

Vaccine Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2016 to 2025

Infectious Vaccine Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2016 to 2025

Collaboration Deals in Pharmaceuticals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Comprehensive deal directory 2020 to 2026

Asset Purchase Deals in Pharmaceuticals and Biotechnology | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Comprehensive deal directory 2019 to 2026

Gene Therapy Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2016 to 2025

Molecular Diagnostics Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2016 to 2025